Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
Open Access
- 5 March 2020
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 14 (5) , 964-973
Abstract
Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aimed to investigate whether AGT promoter methylation in tumor tissue predicts response to bevacizumab combination therapy in patients with recurrent glioblastoma. The study included 159 patients with recurrent glioblastoma, treated with bevacizumab combination treatment (training cohort, n = 77; validation cohort, n = 82). All patients could be evaluated for treatment response and biomarkers. DNA methylation of 4 CpG sites in the AGT promoter was measured using pyrosequencing. A model for nonresponse was established using logistic regression analysis. In the training cohort, lower methylation of each of the four CpG sites in the AGT promoter was significantly associated with nonresponse (all P < 0.05). Moreover, the mean methylation level of all four CpG sites was associated with an increased likelihood of not achieving response to bevacizumab combination therapy (twofold decrease: odds ratio = 3.01; 95% confidence interval: 1.41–6.44; P = 0.004). We developed a model for nonresponse in the training cohort, where a threshold of mean AGT promoter methylation levels was set to below 12%. The model could predict bevacizumab nonresponse with 96% specificity. Importantly, this predictor was also significantly associated with nonresponse in the validation cohort (P = 0.037). Taken together, our findings suggest that low AGT promoter methylation in tumor tissue predicts nonresponse to bevacizumab combination treatment in patients with recurrent glioblastoma. We have, thus, established and successfully validated a predictor for nonresponse that can be used to identify patients who will not benefit from bevacizumab combination therapy.Keywords
Funding Information
- Kræftens Bekæmpelse
- I.M. Daehnfeldt Foundation
- Rigshospitalet
- Genentech
This publication has 31 references indexed in Scilit:
- The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabClinical Cancer Research, 2016
- Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomasNeuro-Oncology, 2015
- Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastomaJournal of Neurology, 2015
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationProceedings of the National Academy of Sciences, 2013
- The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of GlioblastomaThe American Journal of Pathology, 2012
- Normalization of the Vasculature for Treatment of Cancer and Other DiseasesPhysiological Reviews, 2011
- Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a reviewJournal of Neuro-Oncology, 2011
- Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trialNeuro-Oncology, 2010
- The transcriptional network for mesenchymal transformation of brain tumoursNature, 2009
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009